Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers

Trial Profile

NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NTRX 07 (Primary)
  • Indications Alzheimer's disease; Neuropathic pain
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors NeuroTherapia

Most Recent Events

  • 01 Dec 2020 According to a NeuroTherapia media release, this study was supported by an Alzheimer's Association Part the Cloud grant.
  • 01 Dec 2020 Results published in the NeuroTherapia Media Release.
  • 01 Dec 2020 Status changed from active, no longer recruiting to completed, according to a NeuroTherapia media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top